Great news! Thanks for sharing . Roche (Genentech) also recently received approval for a breast cancer treatment that seems quite promising. www.biospace.com/press-releas...
FDA approves Roche’s Itovebi, a targeted treatment for advanced hormone receptor-positive, HER2-negative breast cancer with a PIK3CA mutation
www.biospace.com
December 6, 2024 at 12:47 AM
Great news! Thanks for sharing . Roche (Genentech) also recently received approval for a breast cancer treatment that seems quite promising. www.biospace.com/press-releas...
ITOVEBI (inavolisib) and the Risk of Life-Threatening Ketoacidosis
(for treatment of breast cancer)
(for treatment of breast cancer)
ITOVEBI (inavolisib) and the Risk of Life-Threatening Ketoacidosis - Canada.ca
Two cases of life-threatening or fatal ketoacidosis have been reported in diabetic patients treated with ITOVEBI in the post-market setting. Audience Healthcare professionals involved in the treatme...
recalls-rappels.canada.ca
October 10, 2025 at 3:01 AM
ITOVEBI (inavolisib) and the Risk of Life-Threatening Ketoacidosis
(for treatment of breast cancer)
(for treatment of breast cancer)
La AEMPS inicia informes de posicionamiento de 'Itovebi', para cáncer de mama con mutación PIK3CA, y otros 6 fármacos www.infosalus.com/farmacia/not...
La AEMPS inicia informes de posicionamiento de 'Itovebi', para cáncer de mama con mutación PIK3CA, y otros 6 fármacos
La Agencia Española de Medicamentos y Productos Sanitarios (AEMPS) ha informado este lunes del comienzo...
www.infosalus.com
August 11, 2025 at 4:55 PM
La AEMPS inicia informes de posicionamiento de 'Itovebi', para cáncer de mama con mutación PIK3CA, y otros 6 fármacos www.infosalus.com/farmacia/not...
Here are the key FDA approvals in 2024: Cobenfy for schizophrenia, Duvyzat for Duchenne muscular dystrophy, Rezdiffra for nonalcoholic steatohepatitis and Itovebi for breast cancer. cen.acs.org/policy/regul... #pharma #biopharma #biosky
Key FDA approvals in 2024
2024 authorizations kept a steady clip and gave people some new treatment options
cen.acs.org
December 10, 2024 at 4:37 PM
Here are the key FDA approvals in 2024: Cobenfy for schizophrenia, Duvyzat for Duchenne muscular dystrophy, Rezdiffra for nonalcoholic steatohepatitis and Itovebi for breast cancer. cen.acs.org/policy/regul... #pharma #biopharma #biosky
The final results from the INAVO120 trial showed a near-doubling of progression-free survival for the Itovebi-Ibrance-fulvestrant combo compared to Ibrance-fulvestrant alone in pts with PIK3CA-mutated HR+ HER2- advanced BC with low rates of grade 3 and 4 hyperglycemia. #medsky #oncsky #scicomm 1/3
Roche's Itovebi Poised to Shake up Competitive Landscape for PI3K Inhibitors
In the absence of head-to-head studies, oncologists are looking across pivotal trials and are encouraged by Itovebi's safety and efficacy versus Piqray.
www.precisionmedicineonline.com
November 27, 2024 at 2:01 AM
"The FDA has approved Genentech’s inavolisib (Itovebi) in combination with the CDK4/6 inhibitor palbociclib and the oestrogen-receptor antagonist fulvestrant for endocrine-resistant, PIK3CA-mutated, hormone receptor-positive, HER2-negative breast cancer." #PI3K
www.nature.com/articles/d41...
www.nature.com/articles/d41...
FDA approves PI3Kα inhibitor that does double duty as a degrader
Discover the world’s best science and medicine | Nature.com
www.nature.com
November 28, 2024 at 8:40 AM
"The FDA has approved Genentech’s inavolisib (Itovebi) in combination with the CDK4/6 inhibitor palbociclib and the oestrogen-receptor antagonist fulvestrant for endocrine-resistant, PIK3CA-mutated, hormone receptor-positive, HER2-negative breast cancer." #PI3K
www.nature.com/articles/d41...
www.nature.com/articles/d41...
Roche verbucht mit Brustkrebs-Kandidaten Itovebi Forschungserfolg
#Roche #news
https://www.awp.ch/sharedarticles?articleid=-1993501697
#Roche #news
https://www.awp.ch/sharedarticles?articleid=-1993501697
January 28, 2025 at 6:47 AM
Roche verbucht mit Brustkrebs-Kandidaten Itovebi Forschungserfolg
#Roche #news
https://www.awp.ch/sharedarticles?articleid=-1993501697
#Roche #news
https://www.awp.ch/sharedarticles?articleid=-1993501697
Roche verbessert mit Brustkrebs-Kandidaten Itovebi Überlebenschancen
Der Pharmakonzern Roche stellt am diesjährigen Krebskongress ASCO in Chicago weitere Daten zu seinem Krebs-Kandidaten Itovebi vor. #Roche #news
https://www.awp.ch/sharedarticles?articleid=-1988601040
Der Pharmakonzern Roche stellt am diesjährigen Krebskongress ASCO in Chicago weitere Daten zu seinem Krebs-Kandidaten Itovebi vor. #Roche #news
https://www.awp.ch/sharedarticles?articleid=-1988601040
May 31, 2025 at 12:17 PM
Roche verbessert mit Brustkrebs-Kandidaten Itovebi Überlebenschancen
Der Pharmakonzern Roche stellt am diesjährigen Krebskongress ASCO in Chicago weitere Daten zu seinem Krebs-Kandidaten Itovebi vor. #Roche #news
https://www.awp.ch/sharedarticles?articleid=-1988601040
Der Pharmakonzern Roche stellt am diesjährigen Krebskongress ASCO in Chicago weitere Daten zu seinem Krebs-Kandidaten Itovebi vor. #Roche #news
https://www.awp.ch/sharedarticles?articleid=-1988601040
NEWS: Roche kicks off this year's ASCO with strong data in breast cancer.
pharmaphorum.com/news/asco-25...
pharmaphorum.com/news/asco-25...
ASCO 25: Roche places Itovebi marker in breast cancer
Roche's Itovebi has become the first PI3K inhibitor to extend survival in HR-positive, HER2-negative breast cancer with a PIK3CA mutation
pharmaphorum.com
May 23, 2025 at 1:29 PM
NEWS: Roche kicks off this year's ASCO with strong data in breast cancer.
pharmaphorum.com/news/asco-25...
pharmaphorum.com/news/asco-25...
✨ #ASCO25 ✨
🚨BREAKING: Roche’s Itovebi™ (inavolisib) significantly extends survival in PIK3CA-mutated HR+/HER2- advanced breast cancer
✅ >30% reduction in risk of death vs palbociclib + fulvestrant
📢 Data presented at ASCO 2025 & published in NEJM
🔗 bit.ly/ONCOnews1J-4
#OncoAlert #OncEd #ONCOnews
🚨BREAKING: Roche’s Itovebi™ (inavolisib) significantly extends survival in PIK3CA-mutated HR+/HER2- advanced breast cancer
✅ >30% reduction in risk of death vs palbociclib + fulvestrant
📢 Data presented at ASCO 2025 & published in NEJM
🔗 bit.ly/ONCOnews1J-4
#OncoAlert #OncEd #ONCOnews
June 1, 2025 at 7:39 AM
✨ #ASCO25 ✨
🚨BREAKING: Roche’s Itovebi™ (inavolisib) significantly extends survival in PIK3CA-mutated HR+/HER2- advanced breast cancer
✅ >30% reduction in risk of death vs palbociclib + fulvestrant
📢 Data presented at ASCO 2025 & published in NEJM
🔗 bit.ly/ONCOnews1J-4
#OncoAlert #OncEd #ONCOnews
🚨BREAKING: Roche’s Itovebi™ (inavolisib) significantly extends survival in PIK3CA-mutated HR+/HER2- advanced breast cancer
✅ >30% reduction in risk of death vs palbociclib + fulvestrant
📢 Data presented at ASCO 2025 & published in NEJM
🔗 bit.ly/ONCOnews1J-4
#OncoAlert #OncEd #ONCOnews
While Roche is expecting Itovebi to become a $2 billion/year blockbuster, watch out because the next generation of mutant PI3ka inhibitors from Relay, Scorpion, and Loxo@Lilly are about to report first-in-human results at SABCS next month. Meet me back here in about two weeks for the download. 3/3
November 27, 2024 at 2:01 AM
While Roche is expecting Itovebi to become a $2 billion/year blockbuster, watch out because the next generation of mutant PI3ka inhibitors from Relay, Scorpion, and Loxo@Lilly are about to report first-in-human results at SABCS next month. Meet me back here in about two weeks for the download. 3/3
Cancer du sein : L’UE donne son feu vert à un nouveau traitement
Approuvé en octobre aux #EtatsUnis 🇺🇸, ce traitement pour une forme avancée ou #Métastatique de #CancerDuSein a été homologué par l’ #UE 🇪🇺 et est commercialisé sous le nom d’#Itovebi 💊
www.20minutes.fr/sante/416494...
Approuvé en octobre aux #EtatsUnis 🇺🇸, ce traitement pour une forme avancée ou #Métastatique de #CancerDuSein a été homologué par l’ #UE 🇪🇺 et est commercialisé sous le nom d’#Itovebi 💊
www.20minutes.fr/sante/416494...
L’Europe donne son feu vert à un nouveau traitement du cancer du sein
Approuvé en octobre aux Etats-Unis, ce traitement pour une forme avancée ou métastatique de cancer du sein a été homologué ce mercredi par l'UE et est commercialisé sous le nom d'Itovebi
www.20minutes.fr
July 23, 2025 at 5:46 PM
Cancer du sein : L’UE donne son feu vert à un nouveau traitement
Approuvé en octobre aux #EtatsUnis 🇺🇸, ce traitement pour une forme avancée ou #Métastatique de #CancerDuSein a été homologué par l’ #UE 🇪🇺 et est commercialisé sous le nom d’#Itovebi 💊
www.20minutes.fr/sante/416494...
Approuvé en octobre aux #EtatsUnis 🇺🇸, ce traitement pour une forme avancée ou #Métastatique de #CancerDuSein a été homologué par l’ #UE 🇪🇺 et est commercialisé sous le nom d’#Itovebi 💊
www.20minutes.fr/sante/416494...
Buy Itovebi (enquire about price, availability and access in India) - 247qualitymeds.com/product/inav...
Buy Inavolisib Tablets in India at Best Price | 24/7QualityMeds
Buy inavolisib tablets online in India at a best price with safe import support. Call 24/7QualityMeds at +91 9967979080 for price details and availability.
247qualitymeds.com
September 22, 2026 at 11:09 AM
Buy Itovebi (enquire about price, availability and access in India) - 247qualitymeds.com/product/inav...
Roadmap to Check a Licensed Importer for Itovebi Access
read more: 247qualitymeds.com/blog/buy-ito...
read more: 247qualitymeds.com/blog/buy-ito...
Buy Itovebi Online in India – Roadmap to Licensed Importer Access
Buy Itovebi online in India with this roadmap to check licensed importers, pricing, and safe access to Inavolisib tablets.
247qualitymeds.com
September 12, 2026 at 10:28 AM
Roadmap to Check a Licensed Importer for Itovebi Access
read more: 247qualitymeds.com/blog/buy-ito...
read more: 247qualitymeds.com/blog/buy-ito...
Stage 4 BC - Had to lower my dose of Ibrance twice, 125, 100, now 75. Itovebi lowered once at my request due to high blood sugar, helped somewhat, from 9 to 6mg. Had great improvement on Ibrance 125 for first few months, then not. Added Itovebi since Feb, nearly clear in May. Scan again soon. 👍😀
August 21, 2026 at 2:41 PM
Stage 4 BC - Had to lower my dose of Ibrance twice, 125, 100, now 75. Itovebi lowered once at my request due to high blood sugar, helped somewhat, from 9 to 6mg. Had great improvement on Ibrance 125 for first few months, then not. Added Itovebi since Feb, nearly clear in May. Scan again soon. 👍😀
Navigating Inavolisib Treatment Safely: Adverse Events Explained
Read more: 247qualitymeds-blog.blogspot.com/2026/08/inav...
Read more: 247qualitymeds-blog.blogspot.com/2026/08/inav...
Navigating Inavolisib Treatment Safely: Adverse Events Explained
Inavolisib (Itovebi) 3 mg and 9 mg tablets for PIK3CA-mutated breast cancer treatment. Every patient is different in responding to the same ...
247qualitymeds-blog.blogspot.com
August 11, 2026 at 5:20 AM
Navigating Inavolisib Treatment Safely: Adverse Events Explained
Read more: 247qualitymeds-blog.blogspot.com/2026/08/inav...
Read more: 247qualitymeds-blog.blogspot.com/2026/08/inav...
"Roche Korea wins approval for breast cancer drug targeting PIK3CA-mutated HR+ HER2- patients"
#Caregiving #Healthcare #ElderCare #MedSky
#Caregiving #Healthcare #ElderCare #MedSky
Roche Korea wins approval for breast cancer drug targeting PIK3CA-mutated HR+ HER2- patients
Roche Korea said it has received marketing approval from the Ministry of Food and Drug Safety (MFDS) for Itovebi (ingredient: inavolisib), a targeted therapy for patients with PIK3CA-mutated, hormone receptor-positive (HR+), and human epidermal growth factor receptor 2-negative (HER2-) breast cancer
www.koreabiomed.com
July 30, 2025 at 8:50 PM
"Roche Korea wins approval for breast cancer drug targeting PIK3CA-mutated HR+ HER2- patients"
#Caregiving #Healthcare #ElderCare #MedSky
#Caregiving #Healthcare #ElderCare #MedSky
"Human medicines European public assessment report (EPAR): Itovebi, inavolisib, Status: Opinion"
#Health #Healthcare #ElderCare
#Health #Healthcare #ElderCare
Human medicines European public assessment report (EPAR): Itovebi, inavolisib, Status: Opinion
Human medicines European public assessment report (EPAR): Itovebi, inavolisib, Status: Opinion
www.ema.europa.eu
June 18, 2025 at 9:43 PM
"Human medicines European public assessment report (EPAR): Itovebi, inavolisib, Status: Opinion"
#Health #Healthcare #ElderCare
#Health #Healthcare #ElderCare
Roche anuncia resultados positivos de 'Itovebi' en supervivencia global para #cáncer de mama avanzado
https://www.infosalus.com/farmacia/noticia-empresas-roche-anuncia-resultados-positivos-itovebi-supervivencia-global-cancer-mama-avanzado-20250203151117.html
#investigadores #salud #medicina
https://www.infosalus.com/farmacia/noticia-empresas-roche-anuncia-resultados-positivos-itovebi-supervivencia-global-cancer-mama-avanzado-20250203151117.html
#investigadores #salud #medicina
Roche anuncia resultados positivos de 'Itovebi' en supervivencia global para cáncer de mama avanzado
Roche ha anunciado resultados positivos del análisis de supervivencia global (SG) del estudio fase III...
www.infosalus.com
February 10, 2025 at 1:28 PM
Roche anuncia resultados positivos de 'Itovebi' en supervivencia global para #cáncer de mama avanzado
https://www.infosalus.com/farmacia/noticia-empresas-roche-anuncia-resultados-positivos-itovebi-supervivencia-global-cancer-mama-avanzado-20250203151117.html
#investigadores #salud #medicina
https://www.infosalus.com/farmacia/noticia-empresas-roche-anuncia-resultados-positivos-itovebi-supervivencia-global-cancer-mama-avanzado-20250203151117.html
#investigadores #salud #medicina
Genentech's Itovebi demonstrated OS benefit in advanced breast cancer, phase III trial finds
https://cancerletter.com/clinical-roundup/20250131_10c/
https://cancerletter.com/clinical-roundup/20250131_10c/
Genentech’s Itovebi demonstrated OS benefit in advanced breast cancer, phase III trial finds - The Cancer Letter
Genentech announced positive topline results from the overall survival analysis of the phase III INAVO120 study investigating Itovebi (inavolisib) in combination with palbociclib (Ibrance) and fulvestrant for people with PIK3CA-mutated, hormone receptor-positive, human epidermal growth factor receptor 2-negative, endocrine-resistant, locally advanced or metastatic breast cancer. To access this subscriber-only content please log in or subscribe.If […]
cancerletter.com
February 5, 2025 at 8:00 PM
Genentech's Itovebi demonstrated OS benefit in advanced breast cancer, phase III trial finds
https://cancerletter.com/clinical-roundup/20250131_10c/
https://cancerletter.com/clinical-roundup/20250131_10c/
2/5 Novartis already markets Piqray, a PI3Kα inhibitor — but it shares a key liability with Roche's Itovebi: both hit mutant and wild-type PI3Kα. Inhibiting wild-type drives severe hyperglycemia, constraining how broadly these drugs can be used.
March 22, 2026 at 3:50 PM
2/5 Novartis already markets Piqray, a PI3Kα inhibitor — but it shares a key liability with Roche's Itovebi: both hit mutant and wild-type PI3Kα. Inhibiting wild-type drives severe hyperglycemia, constraining how broadly these drugs can be used.
So between the recent approval of Itovebi and publication of Ph III results and now these first-in-human results for the next batch in development, the picture on targeting mutant forms of PI3ka to avoid hyperglycemia is finally coming into focus. It's looking like big improvement.
December 11, 2024 at 2:09 PM
So between the recent approval of Itovebi and publication of Ph III results and now these first-in-human results for the next batch in development, the picture on targeting mutant forms of PI3ka to avoid hyperglycemia is finally coming into focus. It's looking like big improvement.